

COVID-19 Vaccine Market - Global Outlook and Forecast 2021-2024

https://marketpublishers.com/r/CDDB90B23BDFEN.html

Date: March 2021 Pages: 207 Price: US\$ 3,750.00 (Single User License) ID: CDDB90B23BDFEN

Abstracts

In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Covid-19 Vaccine Market Report

The global COVID-19 vaccine market by revenue is expected to reach a value of USD 5 billion during 2021–2024.

VACCINE PIPELINE INSIGHTS

The global COVID-19 vaccine market size is expected to reach over 5 billion by 2024. Constant focus by government agencies and several vaccine manufacturers to prevent human and economic losses due to the COVID-19 virus across the world is expected to boost the market's growth. With several vendors implementing new strategies, including combining the phase 1 & 2 clinical trial stages and faster regulatory approvals from health agencies, the availability of vaccine doses across the globe is likely to grow during the forecast period.

The following factors are likely to contribute to the growth of the COVID-19 market during the forecast period:

Increased Initiatives for COVID-19 Vaccination

The emergence of Next Generation Vaccine Platforms for COVID-19 Vaccine

Fast Regulatory Approvals for COVID-19 Vaccines



The study considers the COVID-19 vaccine market's present scenario and its market dynamics for the forecast period 2022?2024. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

Global COVID-19 Vaccine Market Segmentation

The global Covid-19 vaccine market research report includes a detailed segmentation by technology, geography. Protein-based vaccines constitute the highest COVID-19 vaccine market share as they contain the purified pieces of pathogen rather than the whole pathogen to trigger the immune response. In the absence of any significant adverse effect on the human body, these vaccines are likely to observe substantial growth during the forecast period. Novavax, Chinese Academy, and GSK/Sanofi are the major manufacturers that have approved protein-based vaccines for emergence use authorization. Protein-based vaccines can be used in patients with compromised immune responses.

By Technology

Vector-based

Nucleic acid-based

Protein-based

Whole Virus

INSIGHTS BY GEOGRAPHY

The outbreak of the COVID-19 pandemic was witnessed across the globe. Countries such as the UK, the US, Italy, Spain, India, China were the most affected; however, Middle East and African countries observed a low to moderate occurrence rate. The APAC market dominated the global COVID-19 vaccine market with over 58% share, followed by Europe with 15% and North America with 12%. The Middle East and Africa, and Latin America accounted for 10 % and 6%, respectively. Since the outbreak of the disease in 2019, which eventually was declared a pandemic by the WHO in March 2020, the spread has been thick and fast, swaying country after country and region after



region.

By Geography

North America

US

Canada

Europe

UK

Germany

France

Spain

Italy

Russia

APAC

China

Japan

South Korea

India

Australia

Latin America

Brazil



Mexico

Middle East & Africa

Saudi Arabia

South Africa

Egypt

UAE

Turkey

INSIGHTS BY VENDORS

AstraZeneca, GlaxoSmithKline, Moderna, Gamaleya, Bharat Biotech, and Pfizer are the major manufacturers of COVID-19 vaccines. Biotechnology and pharmaceutical industries are intensely competitive and are characterized by rapid and significant technological progress in vaccine development. Multiple products have been approved by the USFDA, EU, and other regulatory bodies for emergency use authorization (EUA) worldwide. Many products are manufactured using the latest vaccine platforms in the market.

Prominent Vendors

AstraZeneca

GlaxoSmithKline

Moderna

Gamaleya

Bharat Biotech

Pfizer



Johnson & Johnson

BioNTech

CureVac

Serum Institute of India

Novavax

Sinovac

Sinopharm

Upcoming Vendors

AnGes

AIVITA Biomedical

CanSinoBio

EuBiologics

Genexine

GreenLight Biosciences

Gennova

Heat Biologics

INOVIO

IIBR

Medicago



Symvivo

Valneva

Zydus Cadila

KEY QUESTIONS ANSWERED

1. Which manufacturers are coming up with COVID-19 vaccines in 2021?

2. What are the major challenges faced by vendors in the distribution of the COVID-19 vaccine?

3. What is the size of the COVID-19 vaccine market by 2021?

- 4. Who are the major market players?
- 5. Which regions are likely to generate the largest revenues in 2021?



Contents

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope Of The Study
4.3.1 Market Segmentation by Geography

5 REPORT ASSUMPTIONS & CAVEATS

5.1 Key Caveats5.2 Currency Conversion5.3 Market Derivation

6 MARKET AT A GLANCE

7 INTRODUCTION

7.1 Overview

8 MARKET OPPORTUNITIES & TRENDS

- 8.1 Upcoming COVID-19 Vaccines
- 8.2 COVID-19 Vaccine Initiatives
- 8.3 Emergence of Next-Generation Vaccine Platforms

9 MARKET GROWTH ENABLERS

9.1 Faster Regulatory Approvals Of COVID-19 Vaccine



- 9.2 Rise In Number Of COVID-19 Patients
- 9.3 Contract Manufacturers Accelerating COVID-19 Vaccine Production

10 MARKET RESTRAINTS

- 10.1 COVID-19 Vaccine Distribution Among LMICs
- 10.2 Adverse Events & Negative Impact Of Approved Vaccines
- 10.3 Low Acceptance Of COVID-19 Vaccine

11 MARKET LANDSCAPE

- 11.1 Market Overview
- 11.2 COVID-19 Vaccine Pipeline
- 11.3 Market Size & Forecast
- 11.4 COVID-19 Supply Chain
- 11.5 Role of Contract Manufacturers in Manufacturing COVID-19 Vaccines
- 11.6 Five Forces Analysis
 - 11.6.1 Threat of New Entrants
 - 11.6.2 Bargaining Power of Suppliers
 - 11.6.3 Bargaining Power of Buyers
 - 11.6.4 Threat of Substitutes
 - 11.6.5 Competitive Rivalry

12 TECHNOLOGY

- 12.1 Overview
- 12.2 Vector-Based COVID-19 Vaccine
- 12.2.1 Overview
- 12.3 Nucleic Acid-Based COVID-19 Vaccine
- 12.3.1 Overview
- 12.4 Protein-Based COVID-19 Vaccine
- 12.4.1 Overview
- 12.5 Whole Virus COVID-19 Vaccine
- 12.5.1 Overview

13 GEOGRAPHY

- 13.1 Market Snapshot & Growth Engine
- 13.2 Geographic Overview





14 APAC

- 14.1 Market Overview
- 14.2 Market Size & Forecast
- 14.3 Key Countries
 - 14.3.1 China: Market Size & Forecast
 - 14.3.2 India: Market Size & Forecast
 - 14.3.3 Japan: Market Size & Forecast
 - 14.3.4 South Korea: Market Size & Forecast
 - 14.3.5 Australia: Market Size & Forecast

15 EUROPE

- 15.1 Market Overview
- 15.2 Market Size & Forecast
- 15.3 Key Countries
 - 15.3.1 UK: Market Size & Forecast
 - 15.3.2 Germany: Market Size & Forecast
 - 15.3.3 Italy: Market Size & Forecast
 - 15.3.4 France: Market Size & Forecast
 - 15.3.5 Russia: Market Size & Forecast
 - 15.3.6 Spain: Market Size & Forecast

16 NORTH AMERICA

16.1 Market Overview

16.2 Market Size & Forecast

16.3 Key Countries

16.3.1 US: Market Size & Forecast

16.3.2 Canada: Market Size & Forecast

17 MIDDLE EAST & AFRICA

- 17.1 Market Overview
- 17.2 Market Size & Forecast
- 17.3 Key Countries
- 17.3.1 Turkey: Market Size & Forecast
- 17.3.2 Saudi Arabia: Market Size & Forecast





- 17.3.3 Egypt: Market Size & Forecast
- 17.3.4 South Africa: Market Size & Forecast
- 17.3.5 UAE: Market Size & Forecast

18 LATIN AMERICA

- 18.1 Market Overview
- 18.2 Market Size & Forecast
- 18.3 Key Countries
- 18.3.1 Brazil: Market Size & Forecast
- 18.3.2 Mexico: Market Size & Forecast

19 COMPETITIVE LANDSCAPE

- 19.1 Competition Overview
 - 19.1.1 AstraZeneca
 - 19.1.2 Moderna
 - 19.1.3 Gamaleya
 - 19.1.4 Pfizer
 - 19.1.5 Johnson & Johnson
 - 19.1.6 GlaxoSmithKline
 - 19.1.7 Novavax
 - 19.1.8 Bharath Biotech
 - 19.1.9 CureVac
 - 19.1.10 Serum Institute of India
 - 19.1.11 Sinovac
 - 19.1.12 Sinopharm

20 KEY COMPANY PROFILES

- 20.1 AstraZeneca 20.1.1 Business Overview 20.1.2 Product Offerings 20.1.3 Key Strategies 20.1.4 Key Strengths 20.1.5 Key Opportunities 20.2 GlaxoSmithKline 20.2.1 Business Overview
 - 20.2.2 Product Offerings



20.2.3 Key Strategies

- 20.2.4 Key Strengths
- 20.2.5 Key Opportunities
- 20.3 Moderna
 - 20.3.1 Business Overview
 - 20.3.2 Product Offerings
 - 20.3.3 Key Strategies
 - 20.3.4 Key Strengths
 - 20.3.5 Key Opportunities
- 20.4 Gamaleya
 - 20.4.1 Business Overview
 - 20.4.2 Product Offerings
 - 20.4.3 Key Strategies
 - 20.4.4 Key Strengths
 - 20.4.5 Key Opportunities
- 20.5 Bharat Biotech
 - 20.5.1 Business Overview
 - 20.5.2 Product Offerings
 - 20.5.3 Key Strategies
 - 20.5.4 Key Strengths
 - 20.5.5 Key Opportunities
- 20.6 Pfizer
 - 20.6.1 Business Overview
 - 20.6.2 Product Offerings
 - 20.6.3 Key Strategies
 - 20.6.4 Key Strengths
- 20.6.5 Key Opportunities
- 20.7 Johnson & johnson
 - 20.7.1 Business Overview
 - 20.7.2 Product Offerings
 - 20.7.3 Key Strategies
 - 20.7.4 Key Strengths
- 20.7.5 Key Opportunities
- 20.8 BioNTech
 - 20.8.1 Business Overview
 - 20.8.2 Product Offerings
 - 20.8.3 Key Strategies
 - 20.8.4 Key Strengths
 - 20.8.5 Key Opportunities



20.9 CureVac

- 20.9.1 Business Overview
- 20.9.2 Product Offerings
- 20.9.3 Key Strategies
- 20.9.4 Key Strengths
- 20.9.5 Key Opportunities
- 20.10 Serum Institute of India
 - 20.10.1 Business Overview
 - 20.10.2 Product Offerings
 - 20.10.3 Key Strategies
- 20.10.4 Key Strengths
- 20.10.5 Key Opportunities
- 20.11 Novavax
 - 20.11.1 Business Overview
 - 20.11.2 Product Offerings
 - 20.11.3 Key Strategies
 - 20.11.4 Key Strengths
 - 20.11.5 Key Opportunities
- 20.12 Sinovac
 - 20.12.1 Business Overview
 - 20.12.2 Product Offerings
 - 20.12.3 Key Strategies
 - 20.12.4 Key Strengths
- 20.12.5 Key Opportunities
- 20.13 Sinopharm
 - 20.13.1 Business Overview
 - 20.13.2 Product Offerings
 - 20.13.3 Key Strategies
 - 20.13.4 Key Strengths
 - 20.13.5 Key Opportunities

21 UPCOMING VENDORS

- 21.1 AnGes
- 21.1.1 Business Overview
- 21.2 AIVITABiomedical
- 21.2.1 Business Overview
- 21.3 CanSinoBio
- 21.3.1 Business Overview



21.3.2 Product Offerings 21.4 eubiologics 21.4.1 Business Overview 21.5 Genexine 21.5.1 Business Overview 21.6 GreenLight Bioscience 21.6.1 Business Overview 21.7 Gennova 21.7.1 Business Overview 21.8 Heat Biologics 21.8.1 Business Overview 21.9 INOVIO 21.9.1 Business Overview 21.10 IIBR 21.10.1 Business Overview 21.11 medicago 21.11.1 Business Overview 21.12 Symvivo 21.12.1 Business Overview 21.13 Valneva 21.13.1 Business Overview 21.14 Zydus Cadila 21.14.1 Business Overview

22 REPORT SUMMARY

22.1 Key Takeaways22.2 Strategic Recommendations

23 QUANTITATIVE SUMMARY

23.1 Market By Geography23.2 North America23.3 Europe23.4 APAC23.5 Latin America23.6 Middle East & Africa

24 APPENDIX



24.1 Abbreviations



List Of Exhibits

LIST OF EXHIBITS

Exhibit 1 Global COVID-19 Vaccines Market Exhibit 2 Market Size Calculation Approach 2021 Exhibit 3 Projected Manufacturing Capacity of Lead Companies Producing COVID-19 Vaccines by End of 2021 (in billions) Exhibit 4 Impact of Upcoming COVID-19 Vaccine Exhibit 5 Impact of COVID-19 Vaccine Initiatives Exhibit 6 Impact of Emergence of Next-Generation Vaccine Platforms Exhibit 7 Impact of Faster Regulatory Approvals of COVID-19 Vaccine Exhibit 8 Impact of Rise in Number of COVID-19 Patients Exhibit 9 COVID-19 Cases in Major Regions Exhibit 10 Impact of Contract Manufacturers Accelerating COVID-19 Vaccine Production Exhibit 11 Impact of COVID-19 Vaccine Distribution Among LMICs Exhibit 12 Income Classification by Confirmed Doses Purchased (\$ billions) Exhibit 13 Impact of Adverse Events & Negative Impact of Approved Vaccines Exhibit 14 Impact of Low Acceptance of COVID-19 Vaccine Exhibit 15 People Not Willing to Take COVID-19 Vaccine (% share) Exhibit 16 COVID-19 Vaccines Under Development by Dosage Exhibit 17 COVID-19 Vaccines Under Development by Route of Administration Exhibit 18 Global COVID-19 Vaccines Market 2021–2024 (\$ billion) Exhibit 19 COVID-19 Vaccine Logistics & Distribution Exhibit 20 COVID-19 Vaccine Development 2021 (% share) Exhibit 21 Five Forces Analysis 2021 Exhibit 22 Incremental Growth by Geography 2021 & 2024 Exhibit 23 Global COVID-19 Vaccines Market by Geography Exhibit 24 Global COVID-19 Vaccines Market 2021- 2024 (\$ million) Exhibit 25 Global COVID-19 Vaccines Market 2021- 2024 (% share) Exhibit 26 Production Capabilities of COVID-19 Vaccine Candidates Per Country (millions) Exhibit 27 Income Classification by Confirmed Number of Doses Purchased by Country (Doses in billions) Exhibit 28 APAC COVID-19 Vaccine Market: Incremental Growth versus Absolute Growth Exhibit 29 COVID-19 Vaccines Market in APAC 2021–2024 (\$ billion) Exhibit 30 Incremental Growth in APAC 2021 & 2024



Exhibit 31 COVID-19 Vaccines Market in China 2021–2024 (\$ million) Exhibit 32 COVID-19 Vaccines Market in India 2021–2024 (\$ million) Exhibit 33 COVID-19 Vaccines Market in Japan 2021–2024 (\$ million) Exhibit 34 COVID-19 Vaccines Market in South Korea 2021–2024 (\$ million) Exhibit 35 COVID-19 Vaccines Market in Australia 2021–2024 (\$ million) Exhibit 36 Europe COVID-19 Vaccine Market: Incremental Growth versus Absolute Growth Exhibit 37 COVID-19 Vaccines Market in Europe 2021–2024 (\$ billion) Exhibit 38 Incremental Growth in Europe 2021 & 2024 Exhibit 39 COVID-19 Vaccines Market in UK 2021–2024 (\$ million) Exhibit 40 COVID-19 Vaccines Market in Germany 2021–2024 (\$ million) Exhibit 41 COVID-19 Vaccines Market in Italy 2021–2024 (\$ million) Exhibit 42 COVID-19 Vaccines Market in France 2021–2024 (\$ million) Exhibit 43 COVID-19 Vaccines Market in Russia 2021–2024 (\$ million) Exhibit 44 COVID-19 Vaccines Market in Spain 2021–2024 (\$ million) Exhibit 45 North America COVID-19 Vaccine Market: Incremental Growth vs. Absolute Growth Exhibit 46 COVID-19 Vaccine Developers in North America Exhibit 47 COVID-19 Vaccines Market in North America 2021–2024 (\$ billion) Exhibit 48 Incremental Growth in North America 2021 & 2024 Exhibit 49 COVID-19 Vaccines Market in US 2021–2024 (\$ million) Exhibit 50 COVID-19 Vaccines Market in Canada 2021–2024 (\$ million) Exhibit 51 Middle East & Africa COVID-19 Vaccine Market: Incremental Growth versus Absolute Growth Exhibit 52 COVID-19 Vaccines Market in Middle East & Africa 2021–2024 (\$ billion) Exhibit 53 Incremental Growth in Middle East & Africa 2021 & 2024 Exhibit 54 COVID-19 Vaccines Market in Turkey 2021–2024 (\$ million) Exhibit 55 COVID-19 Vaccines Market in Saudi Arabia 2021–2024 (\$ million) Exhibit 56 COVID-19 Vaccines Market in Egypt 2021–2024 (\$ million) Exhibit 57 COVID-19 Vaccines Market in South Africa 2021–2024 (\$ million) Exhibit 58 COVID-19 Vaccines Market in UAE 2021–2024 (\$ million) Exhibit 59 Latin America COVID-19 Vaccine Market: Incremental Growth versus Absolute Growth Exhibit 60 COVID-19 Vaccine Market in Latin America 2021–2024 (\$ billion) Exhibit 61 Incremental Growth in Latin America 2021 & 2024 Exhibit 62 COVID-19 Vaccines Market in Brazil 2021–2024 (\$ million) Exhibit 63 COVID-19 Vaccines Market in Mexico 2021–2024 (\$ million) Exhibit 64 AstraZeneca Revenue 2017-2019 (\$million) Exhibit 65 AstraZeneca Research & Development Expenditure (\$ million)



Exhibit 66 GlaxoSmithKline Revenue 2017-19 (billions)

Exhibit 67 Moderna Revenue 2017-2019 (\$ million)

Exhibit 68 Moderna Research & Development Expenditure (\$ million)

Exhibit 69 Pfizer Revenue 2017- 2019 (\$ billion)

Exhibit 70 Pfizer Research & Development 2017-2019 (\$ billion)

Exhibit 71 Johnson & Johnson Revenue 2017- 2019 (\$ million)

Exhibit 72 Johnson & Johnson Research & Development 2017-2019 (\$ million)

Exhibit 73 BioNTech Revenue 2017-2019 (million)

Exhibit 74 BioNTech Research & Development 2017-2019 (\$ million)

- Exhibit 75 Novavax Revenue 2017-2019 (million)
- Exhibit 76 Novavax Research & Development Expenditure 2017-2019 (million)



List Of Tables

LIST OF TABLES

Table 1 Key Caveats Table 2 Currency Conversion 2013?2020 Table 3 Up-Coming COVID-19 Vaccines Table 4 Comparison of Up-Coming COVID-19 Vaccine Platforms Table 5 COVID-19 Cases in Top Ten Countries Table 6 COVID-19 Vaccines EUA Approved as of Mid of 2021 January Table 7 COVID-19 Vaccines Approved for Use in Various Countries Table 8 COVID-19 Candidates in Clinical Phase Based on Vaccines Types Table 9 List of COVID-19 Vaccines Under Phase II & III Clinical Trial Table 10 List of COVID-19 Vaccines Under Phase I & II Clinical Trial Table 11 List of COVID-19 Vaccines Under Phase I & Pre-Clinical Trial Table 12 Key companies & CMOs Agreements for COVID-19 Vaccine (millions) Table 13 EUA-Approved COVID-19 Vaccines Table 14 COVID-19 Vaccines Based on Vector Platform Under Development Table 15 COVID-19 Vaccines Based on Nucleic Acid Platform Under Development Table 16 COVID-19 Vaccines Based on Protein Platform Under Development Table 17 COVID-19 Vaccines Based on Whole Virus Platform Under Development Table 18 Regional Confirmed COVID-19 Cases WHO (as of 2021 February) Table 19 Countries with Highest COVID-19 Cases & Deaths Table 20 List of Agreements Signed for COVID-19 Vaccines Table 21 Approved Vaccines for COVID-19 in UK Table 22 UK Agreement with Companies for COVID-19 Vaccine (million) Table 23 List of Agreements Signed for COVID-19 Vaccines Table 24 Approved Vaccines for COVID-19 in US Table 25 US Agreement with Companies for COVID-19 Vaccine (million) Table 26 List of Agreements Signed for COVID-19 Vaccines Table 27 List of Agreements Signed for COVID-19 Vaccines. Table 28 List of Agreements Signed for COVID-19 Vaccines with AstraZeneca Table 29 List of Agreements Signed for COVID-19 Vaccines with Moderna Table 30 List of Agreements Signed for COVID-19 Vaccines with Pfizer Table 31 List of Agreements Signed for COVID-19 Vaccines with Johnson & Johnson Table 32 List of Agreements Signed for COVID-19 Vaccines with GSK Table 33 List of Agreements Signed for COVID-19 Vaccines with Novavax Table 34 List of Agreements Signed for COVID-19 Vaccines with CureVac Table 35 List of Agreements Signed for COVID-19 Vaccines with SinoVac



Table 36 AstraZeneca: Major Product Offerings Table 37 GlaxoSmithKline: Major Product Offerings Table 38 Moderna: Major Product Offerings Table 39 Gamaleya: Major Product Offerings Table 40 Bharat Biotech: Major Product Offerings Table 41 Pfizer: Major Product Offerings Table 42 Johnson & Johnson: Major Product Offerings Table 43 BioNTech: Major Product Offerings Table 44 CureVac: Major Product Offerings Table 45 Serum Institute of India: Major Product Offerings Table 46 Novavax: Major Product Offerings Table 47 Sinovac: Major Product Offerings Table 48 Sinopharm: Major Product Offerings Table 49 CanSinoBio: Major Product Offerings Table 50 Global COVID-19 Vaccines Market by Geography 2021?2024 (\$ million) Table 51 Global COVID-19 Vaccines Market by Geography 2021?2024 (%) Table 52 North America COVID-19 Vaccines Market 2021?2024 (\$ million) Table 53 North America COVID-19 Vaccines Market 2021?2024 (%) Table 54 Europe COVID-19 Vaccines Market 2021?2024 (\$ million) Table 55 Europe COVID-19 Vaccines Market 2021?2024 (%) Table 56 APAC COVID-19 Vaccines Market 2021?2024 (\$ million) Table 57 APAC COVID-19 Vaccines Market 2021?2024 (%) Table 58 Latin America COVID-19 Vaccines Market 2021?2024 (\$ million) Table 59 Latin America COVID-19 Vaccines Market 2021?2024 (%) Table 60 Middle East & Africa COVID-19 Vaccines Market 2021?2024 (\$ million) Table 61 Middle East & Africa COVID-19 Vaccines Market 2021?2024 (%)



I would like to order

Product name: COVID-19 Vaccine Market - Global Outlook and Forecast 2021-2024 Product link: <u>https://marketpublishers.com/r/CDDB90B23BDFEN.html</u> Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

> If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/CDDB90B23BDFEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970